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p65Mutations of the gene encoding sequestosome1 (SQSTM1/p62), clustering in or near the UBA domain, have
been described in Paget's disease of bone (PDB); among these the P392L substitution is the most prevalent.
Protein p62 mediates several cell functions, including the control of NF-κB signaling, and autophagy. This
scaffolding protein interacts with atypical PKCζ in the RANKL-induced signaling complex. We have previous-
ly shown that osteoclasts (OCs) overexpressing the p62P392L variant were in a constitutively activated state,
presenting activated kinase p-PKCζ/λ and activated NF-κB prior to RANKL stimulation. In the present study,
we investigated the relationships between PKCζ and NF-κB activation in human OCs transfected with p62 vari-
ants. We showed that PKCζ and p-PKCζ/λ co-localize with p62, and that PKCζ is involved in the RANKL-induced
NF-κB activation and in the RANKL-independent activation of NF-κB observed in p62P392L-transfected cells. We
also observed a basal and RANKL-induced increase in IκBα levels in the presence of the p62P392L mutation that
contrasted with the NF-κB activation. In this study we propose that PKCζ plays a role in the activation of
NF-κB by acting as a p65 (RelA) kinase at Ser536, independently of IκBα; this alternative pathway could be
used preferentially in the presence of the p62P392L mutation, whichmay hinder the ubiquitin–proteasome path-
way. Overall, our results highlight the importance of p62-associated PKCζ in the overactive state of pagetic OCs
and in the activation of NF-κB, particularly in the presence of the p62P392L mutation.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Paget's disease of bone (PDB) is a skeletal disorder characterized
by focal and disorganized increases in bone turnover [1]. Osteoclasts
(OCs) are the primary cells affected in PDB as the initial phase of
this bone disease is characterized by excessive bone resorption [2].
Pagetic OCs are both larger, and more numerous than normal OCs.
They are also hyperactive and resistant to apoptosis [3]. This disease
has a strong genetic component, and mutations in the SQSTM1/p62
gene have been identiﬁed in a high proportion of PDB patients, the
most frequent being the P392L mutation [4–6]. The SQSTM1/p62
gene encodes the ubiquitin-binding protein sequestosome1, also
known as p62, which mediates various cell functions, including the
control of NF-κB signaling, regulation of autophagy, and gene tran-
scription [7–9]. The presence of multiple protein–protein interaction
domains supports its various functions. In particular, p62 has been
described as a scaffolding protein that, along with TRAF6, interacts
with the receptor activator of NF-κB (RANK) signaling complex,bone; RANKL, receptor activa-
; PKCζ, protein kinase C zeta;
; IκB, inhibitor of NF-κB; IKK,
erbrooke, PQ, Canada J1H5N4.
ux).
rights reserved.formed in response to RANK ligand (RANKL) stimulation, which is the
key regulator of OC formation, activity, and survival. All mutations
that have been reported so far in PDBpatients are clustered either with-
in or near the C-terminal region of the p62 protein that embodies the
ubiquitin-associated (UBA) domain, and affect its ubiquitin-binding ca-
pacities [10–13]. The discovery of mutations in the SQSTM1/p62 gene in
numerous patients has identiﬁed protein p62 as an important modula-
tor of bone turnover. We and others have recently shown that p62
overexpression in PDB, and the PDB-related p62P392L mutation lead to
impaired control of OC survival and activities, thus highlighting the crit-
ical role of p62 in cellular dysfunction in this disease [3,14]. Transgenic
animal models have further demonstrated the impact of the p62muta-
tion in the development of PDB. Knocked-in mice expressing the
p62P394L gene (the murine equivalent of human p62P392L) develop
focal osteolytic lesions, some of which resemble PDB lesions [15], al-
though in another study, co-expression of the measles virus nucleocap-
sid gene (MVNP) in the osteoclast lineage was required [14].
In rodent OCs, early events that occur after RANKL stimulation in-
clude the formation of a multiprotein complex containing p62, TRAF6
and the atypical PKCζ [16]. This complex is required for RANKL-
induced NF-κB activation andNFATc1 synthesis, both resulting in OC dif-
ferentiation and activation [16]. We have previously shown that in re-
sponse to RANKL stimulation, PKCζ and its upstream activator PDK1
(3-phosphoinositide-dependent protein kinase 1) are associated with
p62 in normal human OCs. Moreover, in PDB OCs, this association is
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P392L mutation in p62 contributes to the increased activation of kinases
PKCζ/λ and PDK1, alongwith basal activation of NF-κB, independently of
RANKL stimulation [3].While the functions of RANKL-mediated PKCζ ac-
tivation are not known, studies in various models have shown that acti-
vated PKCζ promotes cell survival by activating the ERK and NF-κB
pathways [17,18] or by intervening in apoptosis cascades [19,20]. Our
present studywas intended to elucidate the relationship between the ac-
tivation of the RANKL signaling kinase PKCζ and that of the NF-κB path-
way, and the impact of the p62P392L mutation in these interactions.
2. Materials and methods
2.1. Materials
Opti Eagle's minimum essential media (Opti-MEM), penicillin,
streptomycin, fungizone, glutamine, and fetal calf serum (FCS) were
purchased from Wisent (Montreal, QC). Ficoll–Paque was purchased
from Amersham Biosciences (Montreal, QC), and antibody diluent
from DAKO (Carpinteria, CA). Human recombinant (hr) M-CSF, and
hrGM-CSF were purchased from R&D (R&D Systems, Minneapolis,
MN); soluble hrRANKL was produced in our laboratory. Goat poly-
clonal anti-p62 (P-15; directed against the C-terminus), rabbit poly-
clonal anti-NFκB (p50 subunit) and anti-inhibitor of NF-κB (IκBα)
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA); mouse monoclonal anti-p62 (IF study), rabbit polyclonal anti-
phospho (Ser311)-p65/RelA and mouse monoclonal anti-phospho-IKKβ
antibodies from Abcam (Cambridge, MA); mouse monoclonal anti-
phospho-IκBα and rabbit monoclonal anti-phospho (Ser536)-p65/RelA
from Cell Signaling Technology (Danvers, MA).We used rabbit polyclon-
al antibodies to detect PKCζ, phospho-PKCζ/λ (Cell Signaling Technolo-
gy), and phospho-PKCλ/ι (Invitrogen, Burlington, ON). A myristoylated
pseudosubstrate peptide inhibitor of PKCζ (Myr-SIYRRGARRWRKL-OH)
was obtained from Millipore (#539624, Billerica, MA). The proteasome
inhibitor MG-132 was purchased from Calbiochem (Mississauga, ON),
Di Aminido Phenyl lndol (DAPI) from Sigma (Oakville, ON), and Alexa
Fluor 633-conjugated phalloidin from Invitrogen.
2.2. Osteoclast cultures
Blood was harvested from human umbilical cord at delivery after
obtaining informed consent from parturient women, as approved by
our institution's review board. Cord blood monocytes (CBMs) were
isolated from heparinized blood by density-gradient centrifugation,
washed, and suspended in Opti-MEM with antibiotics, glutamine,
and 2% FCS. They were plated at a density of 3×106/ml on 8-well
chamber/slides (Lab-Tek, Biosciences, Bedford, MA). After incubating
overnight, the cells were gently washed to remove any non-adherent
cells, and cultured inOpti-MEMsupplementedwithGM-CSF (100 pg/ml)
for the ﬁrst 3 days, and then for a further 3 weeks in the same medium
supplementedwithM-CSF (25 ng/ml) and RANKL (75 ng/ml). Themedi-
um was changed every 2–3 days. These culture conditions generate
multinucleated cells (MNC) that express OCmarkers and have the ability
to resorb bone [3,21]. In all experiments, RANKL stimulations were
performed 48 h after the last change of medium.
2.3. Constructs and transfections
The full coding sequence of SQSTM1 (p62wt) was obtained from
IMAGE clone #2906264 and subcloned into a pEGFP-C2 vector. The
P392L mutation (p62P392L) was generated from the wild-type sequence
by PCR-directed mutagenesis. These GFP-fused constructs had previous-
ly been shownnot to interferewith the normal subcellular localization of
p62 [22]. Differentiated human OCs were transfected in serum-free
OPTI-MEM containing LipoLTX for 6 h with constructs containing an
empty vector (EV), p62 wild type (p62WT) or mutated p62P392L.Transfection efﬁciency was assessed by ﬂuorescence microscopy
24 h after the procedure, and ranged between 40% and 70% in all
cultures. The effective expression of the plasmid was assessed in GFP-
immunoprecipitates by p62 Western blotting (Supplemental Fig. 1).
2.4. Immunoﬂuorescence
Cells were stimulated for various periods of time with 100 ng/ml
of RANKL, washed quickly with cold PBS, and then ﬁxed with 1% para-
formaldehyde. After permeabilization and autoﬂuorescence quenching,
non-speciﬁc binding sites were blockedwith 2% Bovine SerumAlbumin
(BSA). Speciﬁc antibodies directed against p62, PKCζ, p-PKCζ/λ, and
p-PKCλ/ι were incubated in antibody diluent overnight at 4 °C.
Alexa-546 (red) anti-rabbit antibodies, Alexa-488 (green) anti-mouse
antibodies or Alexa Fluor 633-conjugated phalloidin were incubated
for 2 h at room temperature. DAPI counter-staining was performed,
so that OCs containing more than three nuclei could be visualized.
Sequences of pictures were taken with appropriate ﬁlters to show all
three colors, and superimposed using Simple PCI software.
2.5. Cell fractionation and Western-blotting
Cells were differentiated as described above, and stimulated with
100 ng/ml of RANKL for 45 min. Nuclear and cytoplasmic cell frac-
tions were isolated using the Q-Proteome Cell Fractionation kit
(Qiagen, Mississauga, ON), according to the manufacturer's instruc-
tions. Brieﬂy, lysis was performed in a series of buffers, and differen-
tial centrifugation made it possible to recover cell fractions enriched
with cytosolic or nuclear proteins. Protein lysates were quantiﬁed
by a modiﬁed Bradford assay (Bio Rad, Mississauga, ONT) and run
through SDS-PAGE. Western-blots were performed by incubating a
primary antibody (anti-p62, anti-p50, or anti-p-PKCζ/λ antibodies
where appropriate) overnight at 4 °C. HRP-conjugated secondary an-
tibodies were used to achieve detection with a chemiluminescent
system. Themembranes were stripped and probed again when neces-
sary, and anti-nuclear lamin or anti-actin antibodies were used as
controls for the nuclear and cytoplasmic fractions respectively.
2.6. Immunoprecipitation and Western-blotting
Cells were cultured as described above. After stimulation, the cells
were lysed for 20 min in a buffer containing NP40, and a cocktail of
protease/phosphatase inhibitors. Lysates were pre-cleared with goat
or rabbit serum followed by A/G agarose bead precipitation. Lysates
were then subjected to overnight immunoprecipitation (IP) at 4 °C
with antibodies directed against p62, GFP or IκBα. Immune com-
plexes were recovered with protein A/G agarose beads, and loaded
onto SDS-PAGE.Western-blots were performed by incubating speciﬁc
primary antibodies overnight at 4 °C. HRP-conjugated secondary an-
tibodies were used to achieve detection with a chemiluminescent
system. Resulting ﬁlms were scanned and densitometric analyses
were performed with ImageJ software.
2.7. Kinase assay
The PKC kinase assay was adapted from a published method [23].
OCs cultured in medium supplemented with M-CSF and RANKL were
incubated in the presence of a myristoylated pseudosubstrate (Myr-
SIYRRGARRWRKL-OH) at 10 μM or diluent control for 30 min. Cells
were disrupted by NP-40 lysis as previously described, and lysates
were immunoprecipitated with anti-PKCζ or anti-PKCλ/ι antibodies.
Immunoprecipitates were washed in lysis buffer (with NP-40 and
NaCl) and resuspended in 20 μl kinase buffer (20 mM HEPES, pH
7.2, 10 mM MgCl2, 5 mM DTT, 20 nM ATP, 0.05% NP-40) containing
dephosphorylated myelin basic protein (MBP), a PKC substrate, and
0.5 μl [γ-32P]ATP (10 mCi/ml). After 15 min, reactions were stopped
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migrated on SDS-PAGE gel prior to autoradiography.
2.8. Statistical analysis
Results were expressed as the mean±standard deviation (SD),
and the signiﬁcance was determined by a paired Student's t-test or
analysis of variance (ANOVA) with Tukey's post-test where appropri-
ate. Statistical signiﬁcance was deﬁned as pb0.05.
3. Results
3.1. Phospho-PKCζ/λ binds to and co-localizes with p62
To investigate the relationships between PKCζ and the p62-driven ac-
tivation of NF-κB in the activation of OCs, we ﬁrst analyzed the interac-
tions between the activated form of PKCζ (p-PKCζ) and p62 in normal
OCs. In OC cultures derived from CBMs, short-term kinetic study indicat-
ed that RANKL stimulation induced the binding of p-PKCζ/λ to p62 as
shown in time-dependent association of p62 immunoprecipitates
(Fig. 1a). Using immunoﬂuorescence, p62 and p-PKCζ/λ were both
shown to be co-localized in or around the nuclei 45 min after RANKL-
stimulation, as were p62 and PKCζ; p-PKCλ/ι, although expressed in os-
teoclasts, did not co-localize with p62 in these conditions, but rather
with the actin ring at the cell periphery (Fig. 1b).a
b
Fig. 1. PKCζ and p62 interactions in human osteoclasts. At the end of CBM cultures, the cells
a) Immunoprecipitations (IPs) were conducted with an anti-p62 antibody in cell lysates. West
(ODs) for bands corresponding to p-PKCζ/λ were corrected with the OD obtained for bands c
ments). Analyses are reported as mean ratio±SD. *pb0.05; **pb0.01; ***pb0.001 vs. nonstim
against p62, PKCζ, p-PKCζ/λ, p-PKCλ/ι. Actin ﬁlaments were stained with Alexa Fluor 633-con
PKCζ and p-PKCζ/λ, p-PKCλ/ι (Alexa-594, red) and nuclei (DAPI, blue). Typical cells are shown3.2. PKCζ is involved in the RANKL-induced activation of NF-κB in osteoclasts
and their precursors
p62 plays a critical role in RANKL-induced NF-κB activation in OCs.
So we next investigated whether the RANKL-induced p62/PKCζ inter-
actions were actually related to the activation of NF-κB, using a
myristoylated pseudosubstrate for PKCζ in NF-κB activation assays.
The speciﬁcity of this inhibitor for PKCζ was determined in OCs by
performing a kinase assay (Fig. 2a). OCs from CBMs were then cul-
tured in the presence of the myristoylated pseudosubstrate before
undergoing RANKL stimulation, and then lysed and fractionated into
nuclei- or cytoplasmic-enriched fractions. As shown in Fig. 2b, adding
RANKL to non-transfected OC cultures increased the nuclear translo-
cation of the NF-κB p50 subunit (ratio of nuclear/cytoplasmic p50:
0.56±0.04 vs. 0.24±0.09 in untreated cells, pb0.05). This effect
was prevented by preincubating the cells with a PKCζ inhibitor before
adding RANKL, suggesting that PKCζ is involved in the RANKL-
induced NF-κB activation in human OCs.
We had previously reported that the p62P392L mutation enhanced
the association between p62 and activated p-PKCζ/λ, and that NF-κB
activation was constitutively increased in OCs expressing the mutated
form of p62 (p62P392L) [3]. In this study, we therefore investigated the
potential role of the p62P392L mutation in the PKCζ-related NF-κB ac-
tivation using OC cultures transfected with p62 variants or an empty
vector (EV). In EV-transfected cells, we observed results similar towere either stimulated with RANKL (100 ng/ml) for the time indicated or left untreated.
ern blots (WBs) with anti-p-PKCζ/λ and anti-p62 antibodies are shown. Optical densities
orresponding to p62, and computed in graphical representations (3 independent experi-
ulated cells. b) Immunoﬂuorescence studies were performed using antibodies directed
jugated phalloidin. Images taken with appropriate ﬁlters reveal p62 (Alexa-488, green),
and represent about 75% of MNCs observed in 2 experiments.
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Fig. 2. Effect of a PKCζ inhibitor on NF-κB nuclear translocation. OC cultures supplemented with M-CSF and RANKL were incubated in the presence of a myristoylated
pseudosubstrate (Myr-SIYRRGARRWRKL-OH) at 10 μM or diluent control for 30 min. PKCζ or PKCλ/ι immunoprecipitates were analyzed in a kinase assay using myelin basic
protein (MBP) as substrate. The relative ratios are indicated (vs absence of PKCζ inhibitor). The data shown are representative of 2 independent experiments (a). At the end of
CBM cultures, the cells were transfected with a pEGFP-C2 plasmid containing p62wt, p62P392L, or an empty pEGFP vector (EV), or were not transfected. Non-transfected cells
(b), or cells transfected with vectors containing p62 variants (c) were preincubated with a myristoylated PKCζ pseudo-substrate at 10 μM for 30 min, and then stimulated with
RANKL (RL) 100 ng/ml for 30 min or left untreated (no RL). Lysates were separated into fractions enriched with nuclear or cytoplasmic proteins. Western blots were performed
with an anti-p50 (NF-κB) subunit antibody, and after membrane stripping, with anti-actin or anti-lamin antibodies for the cytoplasmic or nuclear fractions respectively. Western
blots (WB) of the cytoplasmic and nuclear fractions are shown. ODs were measured with ImageJ software, and the ratios of p50 to lamin (nuclear fraction) over p50 to actin
(cytoplasmic fraction) were computed. Analyses are reported as the mean ratio±SD. *pb0.05, **pb0.01 vs untreated, #pb0.05, ##pb0.01 absence vs presence of PKCζ inhibitor,
°pb0.05 vs EV. The data are representative of 3 independent experiments.
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expressed, we observed a non-signiﬁcant increase in the nuclear
expression of p50. No further increase was detected after adding
RANKL, nor was this modiﬁed by the presence of the PKCζ inhibitor.
In contrast, cells transfected with the mutant form of p62 (p62P392L)
exhibited a signiﬁcantly higher nuclear expression of p50 compared
to EV-transfected cells, even prior to RANKL stimulation (0.58±0.1
p62P392L vs. 0.27±0.03 EV, pb0.05). Moreover, after adding RANKL,
the ratio of nuclear/cytoplasmic p50 was further increased to 1.09±
0.09 in p62P392L cells, and was signiﬁcantly greater than that in the
untreated cells (0.58±0.1, pb0.05). Preincubating p62P392L-expressing
cells with the PKCζ inhibitor markedly reduced the nuclear expression
of p50 both in the presence of RANKL (0.19±0.04) and in its absence
(0.36±0.07), to values not signiﬁcantly different from those observed
in untreated, EV-transfected cells. This indicates overall that PKCζ
plays a critical role in both the basal and RANKL-induced over-
activation of NF-κB in OCs expressing the p62P392L mutation.
3.3. P62P392L mutation modiﬁes the canonical NF-κB signaling pathway
We next considered how PKCζ could intervene in NF-κB activa-
tion, particularly in the presence of the p62P392L mutation. The activa-
tion of NF-κB normally involves the inactivation of IκB (Inhibitor of
NF-κB), its release from NF-κB, and the subsequent nuclear transloca-
tion of IκB-free NF-κB subunits (p50/p65), required for RANKL-
stimulated OCs to differentiate and function properly. The p62-
driven NF-κB activation may involve either its scaffold properties
facilitating kinase cascade activation to free IκBα, or its polyubiquitin
chain binding properties facilitating IκBα proteasome degradation. To
further investigate the role of p62 and of the p62P392L mutation in the
activation of NF-κB, we ﬁrst evaluated the expression of IκBα in OCs
with and without RANKL stimulation. As p62 may contribute to the
proteasome-mediated degradation of IκB, we analyzed IκBα expres-
sion in cells which had been preincubated with MG132, a potent
proteasome inhibitor. As shown in Fig. 3a, IκBα was time-
dependently degraded within the ﬁrst 30 min after adding RANKL.
However, when MG132 was added to the culture medium 30 min be-
fore adding RANKL, no obvious degradation of IκBαwas seen after the
addition of RANKL (Fig. 3a). The same results were obtained in cells
transfected with an empty vector, thus suggesting that the transfection
process did not modify IκBα degradation. However, when p62wt was
overexpressed in human OCs, lower levels of IκBα were detected in
contrast to control cells transfected with an empty vector; these
remained stable in the presence of RANKL, but increased considerably
in the presence of a proteasome inhibitor (Fig. 3b). These results suggest
that p62 overexpression induced accelerated degradation of IκBα, but
that this was blocked in the presence of MG-132. In cells carrying the
p62P392L mutation, increased expression of IκBα was detected in
non-stimulated cells at a level signiﬁcantly higher than that in p62wt
transfected cells, and which remained relatively high with or without
RANKL stimulation in the presence of the proteasome inhibitor. This in-
crease in IκBαwas surprising, contrasting with the increased activation
of NF-κB observed under basal conditions in these cells.
3.4. P62P392L mutation affects IκBα degradation
The high level of IκB observed in cells expressing p62P392L might
have been a result of a defect in the IκBα degradation process. Indeed,
p62 may contribute to the degradation of IκB as a result of its associa-
tion with the proteasome, and the presence of a UBA domain at its
C-terminus, which binds non-covalently to polyubiquitin chains [24].
Thus, the p62P392L mutation could interfere with the degradation of
IκBα via altered interactions between a mutated UBA domain that
may not bind properly to ubiquitinated IκBα. We therefore investigated
whether p62 could be associated with IκBα, and whether the p62P392L
mutation could modify this interaction.Cells were stimulated for various lengths of time with 100 ng/ml
of RANKL, lysed and subjected to immunoprecipitation using anti-
p62 antibodies in non-transfected cells. Western blots were per-
formed with anti-IκBα antibodies. As shown in Fig. 4a, p62 and
IκBα were associated physically in a time-dependent manner in
non-transfected cells stimulated with RANKL. Accordingly, the re-
verse immunoprecipitation of IκBα also revealed the presence of
p62. Similar experiments were conducted in cells transfected with
anEV, awild-type formof p62 or a p62 vector carrying the p62P392Lmu-
tation (Fig. 4b). As these p62mutants were fused to a GFP encoding se-
quence, we precipitated the ectopic p62 using an anti-GFP antibody.
After RANKL stimulation of cells overexpressing p62wt, a high level of
association of p62 with IκBα was detected (3 times higher than in
non-treated cells, pb0.05). This was not observed in cells transfected
with an EV, thus indicating that the GFP ﬂag did not modify p62/IκBα
interaction. In contrast, in cells expressing the p62P392L variant, the in-
teraction of p62 with IκBα in the presence of RANKL was not signiﬁ-
cantly different from that in the untreated cells, thus indicating that
the p62 mutation alters the function of p62 in NF-κB signaling by de-
creasing its capacity to bind IκBα, and thus to shuttle this factor towards
the proteasome.
3.5. PKCζ may act as an IKK kinase in osteoclasts
Atypical PKCs and p62 are part of the RANKL-signaling complex,
and PKCζ could potentially act as an IKK (IκB kinase) in the
p62-driven activation of NF-κB in OCs, as has been shown in
non-OC cells [25,26]. Hence, PKCζ could contribute to the upstream
activation/phosphorylation of IKK, which results in the activation
of NF-κB, and if so, the p62P392L mutation may have an impact on
this function. To explore this possibility, we studied the phosphory-
lation of IKKβ, the regulatory subunit of the IKK complex, in the pres-
ence of an inhibitor of PKCζ, and then stimulated for 3 min or 30 min
with RANKL (Fig. 5a, b). While no signiﬁcant changes in the levels
of p-IKKβ and p-IκBα were observed after short-term RANKL stimu-
lation (3 min) (Supplemental Fig. 2), the expression of p-IKKβ was
signiﬁcantly increased after a 30-min RANKL stimulation in
EV-transfected OCs, and this increase was prevented in the presence
of the inhibitor of PKCζ in these cells. No signiﬁcant modulations
of p-IKKβ were observed in p62wt-transfected OCs. In
p62P392L-transfected OCs, the basal expression of p-IKKβ was signif-
icantly lower in the presence of the inhibitor of PKCζ, and increased
after RANKL-stimulation. However, p-IKKβ expression was not sig-
niﬁcantly different in p62P392L-transfected OCs compared to EV-
transfected cells, whether in the presence of the inhibitor of PKCζ
or not. While these results demonstrate a possible role of PKCζ as
an IKK kinase in the RANKL-induced activation of NF-κB in OCs,
they did not suggest that this kinase activity makes anymajor contri-
bution to the activation of NF-κB observed in the presence of the
p62P392L mutation.
3.6. PKCζ acts as a p65 kinase independently of IκBα
We found that in the presence of p62P392L, the expression of IκBα
increased even in the absence of RANKL, and that an alteration of
IκBα degradation may be at least partially responsible for this. How-
ever, this increase in IκBα contrasts with the simultaneous increased
activation of NF-κB observed under basal or RANKL-stimulated condi-
tions in the p62P392L-expressing cells. Because of the involvement of
PKCζ in the activation of NF-κB observed in these cells, we hypothe-
sized that PKCζ may directly phosphorylate p65 (RelA) to activate
the NF-κB pathway, independently of IκB [27]. The expression
of p-Ser536 or p-Ser311p65 was evaluated by Western blot in non-
transfected cells, and in cells transfected with p62 variants or EV. In
non-transfected OCs, the expression of p-Ser536p65, but not that of
p-Ser311p65, was signiﬁcantly increased in the presence of RANKL,
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(Fig. 6a). In transfected cells, the expression of p-Ser536p65 was in-
creased in the presence of RANKL, with a stronger activation occur-
ring in the presence of the p62P392L variant (Fig. 6b). In addition,
preincubating p62P392L-expressing cells with the PKCζ inhibitormarkedly reduced the expression of p-Ser536p65 both in the presence
of RANKL and in its absence, to values not signiﬁcantly different from
those observed in untreated, EV-transfected cells. These results sug-
gest that PKCζ was involved not only in the p62-driven activation of
NF-κB induced by RANKL, but also in the basal activation of NF-κB
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RelA pathway. Activation of this pathway could explain the NF-κB ac-
tivation in OCs even in the presence of high levels of IκBα, and could
be preferentially used in the presence of the p62P392L mutation.
4. Discussion
The formation of a ternary complex between TRAF6, p62 and atyp-
ical PKCs in response to RANKL stimulation has been reported in ro-
dent OCs [16]. In human OCs RANKL stimulation has been shown to
induce the formation of a multiprotein complex that not only con-
tains PKCζ and p62, but also PDK1, the substrates of which include
PKCζ [3]. In PDB OCs, and in OCs overexpressing wild-type and
p62P392L, the formation of activated kinase/p62 complexes is consti-
tutive, although only the mutated gene led to an increased basal
level of NF-κB activation [3]. These data identify p62 as an important
mediator in osteoclastogenesis, and suggest that p62P392L contributes
to the formation of over-active OCs through signaling pathwaysinvolving PDK1, PKCζ/λ and NF-κB. To explore the relationship be-
tween the constitutive activation of PKCζ, and that of NF-κB previous-
ly reported in the presence of the p62P392L mutation [3], NF-κB
activation was investigated after inhibiting PKCζ. In normal OCs,
RANKL increased nuclear translocation of the p50 subunit of NF-κB,
and this was prevented by a PKCζ inhibitor, indicating that part of
the RANKL-induced activation of NF-κB is related to PKCζ. In OCs
overexpressing p62P392L, but not in p62wt OCs, an increase in the activa-
tion of NF-κB was observed even prior to RANKL stimulation, and this
was considerably reduced in the presence of a PKCζ inhibitor. Thus
PKCζ appears to be involved not only in the RANKL-induced activation
of NF-κB, but also in the basal, non-stimulated, activation of NF-κB ob-
served in p62P392L-transfected cells. Among aPKCs, PKCλ might also
have an important role in OC signaling. Like PKCζ, PKCλ has been
shown to interactwith p62. In addition, the loss of PKCζ does not impair
RANKL-induced osteoclastogenesis [16]. Thus, it has been speculated
that, at least in mice, p62/PKCλ may be necessary for NF-κB activation
[28].
b 
a 
Fig. 5. Expression of p-IKK in the presence of a PKCζ inhibitor. At the end of CBM cultures, the
cells were transfected with a pEGFP-C2 plasmid containing p62wt, p62P392L, or an empty
pEGFP vector (EV). Cells were preincubated with a myristoylated PKCζ pseudo-substrate at
10 μM for 30 min, and then stimulated with RANKL 100 ng/ml for 30 min or left untreated
(No RANKL). a) Whole cell lysates were subjected to Western blotting using an anti-p-
IKKβ, and after membrane stripping, with anti-actin antibodies. Western blots (WB) are
shown. b) ODs were measured with ImageJ software. Protein expressions were normalized
relative to the respective actin intensity, and the results are expressed as the expression
relative to that of the untreated EV-transfected cells (mean±SD). * pb0.05, ** pb0.01 vs
untreated, # pb0.05, absence vs presence of PKCζ inhibitor. The data shown are representa-
tive of 5 independent experiments.
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tion of IκB, its release from NF-κB, and the subsequent nuclear trans-
location of IκB-free NF-κB subunits (p50/p65). Phosphorylation
targets IκB for ubiquitination and proteosomal degradation. In the
present paper, we observed in OC cultures that the expression of
IκBα was greater in the presence of the p62P392L mutation than in
p62wt-transfected cells. p62 is known to shuttle proteins towards
the proteasome for degradation [24], andmutations in the UBA domain
may interfere with the proteosomal degradation of polyubiquitinylated
proteins directly, or indirectly through UBA structural changes [29–31].
Our results indicate that p62 contributes to IκBα degradation by a direct
association. The high levels of IκBα detected in presence of the p62P392L
mutation are thus likely related to a less effective binding of IκBα to
p62, resulting in defective IκBα clearance in mutated Ocs, in addition
to the NF-κB-induced IκB gene expression [27]. Consistent with the
ﬁndings of studies using other models, it seems that a functional UBA
domain is required to achieve p62-dependent proteasomal functions
[32].
However, impaired IκBα degradation should lead to a decrease in
the activation of the NF-κB remaining in the cytoplasm [33]. This has
been reported in rodent OCs, where proteosomal inhibitors suppressed
RANKL-induced osteoclastogenesis by altering IκBα degradation [34].
As the effect of the p62P392L mutation is in contrast an over-activation
of NF-κB, our ﬁndings suggest that although IκBα clearance is indeed
impaired, this could be outweighed in p62P392L cells by other mecha-
nisms that stimulate NF-κB activation.
Depending on the system, PKCζ may activate NF-κB by acting as
an IKK kinase, or may act downstream of IKK by controlling thetranscriptional activity of the NF-κB complex [9]. In non-OC cells,
PKCζ has been shown to be involved in the p62-drivenNF κB activation,
responsible for the phosphorylation of the IκB kinase IKKβ [25,35], and
IKKβ could be recruited to the multiprotein complex including p62,
TRAF6 and PKCζ [32]. In addition, IKKβ overactivation is able to drive
osteoclastogenesis even in the absence of RANKL [36]. Our results sug-
gest that PKCζ may act as an IKK kinase in the RANKL-induced activa-
tion of NF-κB in OCs, but did not suggest that this kinase activity
makes any major contribution to the activation of NF-κB observed in
the presence of the p62P392L mutation.
Mechanisms other than the cytosolic degradation of IκB may reg-
ulate NF-κB activation, such as the phosphorylation of p65 (Rel A),
one subunit of the NF-κB dimer [37]. The phosphorylation of p65
may occur at speciﬁc serine residues in nucleus or cytoplasm,
depending on the kinase, stimulus and cell type [38]. The direct phos-
phorylation of p65 enhances its transactivation potential, but may
also reduce its afﬁnity for IκB, and induce its translocation to the nu-
cleus independently of IκB degradation [27]. Various kinases have
been reported to phosphorylate p65, such as MAP3K NIK (NF-κB-in-
ducing kinase) [39] or IKKs at residue Ser536 [40], casein kinase II
at Ser529 [41] and PKCζ at Ser311 [42]. In human Saos cells, p53-
stimulated RSK1 (ribosomal S6 kinase-1) has been shown to phos-
phorylate nuclear p65 at Ser536, reducing its afﬁnity for IκBα, and
leading to decreased IκBα-mediated nuclear export of the p-p65/
p50 complex [43]. In murine OC precursors, RANKL has been reported
to induce p65 phosphorylation at Ser536 via TAK1 (TGF β-activated
kinase 1)-MKK6-p38 pathway, independently of the RANKL-induced
phosphorylation and degradation of IκB [44]. In our study, we evaluated
the expression of p65 phosphorylated at Ser536 and Ser311 in CBM-
derived OCs, and we found that the RANKL-induced p-Ser536p65 levels
were altered by inhibiting PKCζ. This was further highlighted in OCs
expressing p62P392L mutation, suggesting that the PKCζ/p65 pathway
contributes to the basal activation of NF-κB in these cells.
Our observations of PKCζ and IκBα expression/degradation high-
light a critical divergence between OCs expressing mutated and
non-mutated p62: when the p62 UBA domain is affected, PKCζ may
be a preferential pathway to NF-κB activation through the phosphor-
ylation of p65. While the mechanisms involved in the over-activation
of PKCζ in the presence of p62P392L mutation remain to be investigat-
ed, one possibility is that the conformational changes resulting from
mutations in the UBA domain could modify the protein-protein inter-
actions involved in the multiprotein complex formed around p62, and
thus promote the interaction between the p62 N-terminal PB1 do-
main and PKCζ, and its activation [30,45].
Previous studies had indicated that overexpression of the p62P392L
mutant in HEK293 or Cos-1 cells increased basal and RANKL-induced
NF-κB activation, more than overexpression of the p62 wild type mu-
tant [46]. However, little is known about the effects of the p62P392L
mutation on osteoclast signaling in humans, although somes studies
have demonstrated the impact of the p62 mutant on OC precursor
signaling. An increase in the RANKL-induced NF-κB, p38 MAPK and
NFATc1 activation was reported in murine OC precursors in the pres-
ence of the p62P392L or p62P394L mutation [14,47]. We analyzed here
the impact of the p62P392L mutation on human mature OCs, but its ef-
fects on signaling pathways during OC differentiation is an important
aspect that requires further studies.
Although the presence of the p62P392L substitution cannot account
for all aspects of the pagetic osteoclast phenotype [14], it clearly af-
fects osteoclast behavior and signaling pathways. p62 overexpression
in PBD OCs contributes to the overactive phenotype of these cells, and
the p62P392L mutation induces some speciﬁc effects [3]. Overall, our
ﬁndings provide new insights into the p62-linked pathways leading
to NF-κB activation in human OCs, and highlight the crucial role of
PKCζ in the uncontrolled activation of PDB OCs, whichmay contribute
to the increased resistance to OC apoptosis and to the excessive bone
resorption observed in pagetic lesions.
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